293 related articles for article (PubMed ID: 23204544)
21. Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers.
Jain R; Poisson L; Narang J; Gutman D; Scarpace L; Hwang SN; Holder C; Wintermark M; Colen RR; Kirby J; Freymann J; Brat DJ; Jaffe C; Mikkelsen T
Radiology; 2013 Apr; 267(1):212-20. PubMed ID: 23238158
[TBL] [Abstract][Full Text] [Related]
22. High-resolution steady-state cerebral blood volume maps in patients with central nervous system neoplasms using ferumoxytol, a superparamagnetic iron oxide nanoparticle.
Varallyay CG; Nesbit E; Fu R; Gahramanov S; Moloney B; Earl E; Muldoon LL; Li X; Rooney WD; Neuwelt EA
J Cereb Blood Flow Metab; 2013 May; 33(5):780-6. PubMed ID: 23486297
[TBL] [Abstract][Full Text] [Related]
23. Prediction of survival in patients affected by glioblastoma: histogram analysis of perfusion MRI.
Romano A; Pasquini L; Di Napoli A; Tavanti F; Boellis A; Rossi Espagnet MC; Minniti G; Bozzao A
J Neurooncol; 2018 Sep; 139(2):455-460. PubMed ID: 29721752
[TBL] [Abstract][Full Text] [Related]
24. Visual inspection of MR relative cerebral blood volume maps has limited value for distinguishing progression from pseudoprogression in glioblastoma multiforme patients.
Kerkhof M; Tans PL; Hagenbeek RE; Lycklama À Nijeholt GJ; Holla FK; Postma TJ; Straathof CS; Dirven L; Taphoorn MJ; Vos MJ
CNS Oncol; 2017 Oct; 6(4):297-306. PubMed ID: 28984142
[TBL] [Abstract][Full Text] [Related]
25. Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.
Schmainda KM; Zhang Z; Prah M; Snyder BS; Gilbert MR; Sorensen AG; Barboriak DP; Boxerman JL
Neuro Oncol; 2015 Aug; 17(8):1148-56. PubMed ID: 25646027
[TBL] [Abstract][Full Text] [Related]
26. Association of overall survival in patients with newly diagnosed glioblastoma with contrast-enhanced perfusion MRI: Comparison of intraindividually matched T1 - and T2 (*) -based bolus techniques.
Bonekamp D; Deike K; Wiestler B; Wick W; Bendszus M; Radbruch A; Heiland S
J Magn Reson Imaging; 2015 Jul; 42(1):87-96. PubMed ID: 25244574
[TBL] [Abstract][Full Text] [Related]
27. Consecutive acquisition of time-resolved contrast-enhanced MR angiography and perfusion MR imaging with added dose of gadolinium-based contrast agent aids diagnosis of suspected brain metastasis.
Tsuchiya K; Aoki S; Shimoji K; Mori H; Kunimatsu A
Magn Reson Med Sci; 2013; 12(2):87-93. PubMed ID: 23666159
[TBL] [Abstract][Full Text] [Related]
28. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected].
Lev MH; Ozsunar Y; Henson JW; Rasheed AA; Barest GD; Harsh GR; Fitzek MM; Chiocca EA; Rabinov JD; Csavoy AN; Rosen BR; Hochberg FH; Schaefer PW; Gonzalez RG
AJNR Am J Neuroradiol; 2004 Feb; 25(2):214-21. PubMed ID: 14970020
[TBL] [Abstract][Full Text] [Related]
29. Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging.
Choi YJ; Kim HS; Jahng GH; Kim SJ; Suh DC
Acta Radiol; 2013 May; 54(4):448-54. PubMed ID: 23592805
[TBL] [Abstract][Full Text] [Related]
30. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.
Liu ZC; Yan LF; Hu YC; Sun YZ; Tian Q; Nan HY; Yu Y; Sun Q; Wang W; Cui GB
BMC Med Imaging; 2017 Feb; 17(1):10. PubMed ID: 28143434
[TBL] [Abstract][Full Text] [Related]
31. The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study.
Neuwelt EA; Várallyay CG; Manninger S; Solymosi D; Haluska M; Hunt MA; Nesbit G; Stevens A; Jerosch-Herold M; Jacobs PM; Hoffman JM
Neurosurgery; 2007 Apr; 60(4):601-11; discussion 611-2. PubMed ID: 17415196
[TBL] [Abstract][Full Text] [Related]
32. Voxel-based evidence of perfusion normalization in glioblastoma patients included in a phase I-II trial of radiotherapy/tipifarnib combination.
Ken S; Deviers A; Filleron T; Catalaa I; Lotterie JA; Khalifa J; Lubrano V; Berry I; Péran P; Celsis P; Moyal EC; Laprie A
J Neurooncol; 2015 Sep; 124(3):465-73. PubMed ID: 26189058
[TBL] [Abstract][Full Text] [Related]
33. Primary central nervous system lymphoma and atypical glioblastoma: multiparametric differentiation by using diffusion-, perfusion-, and susceptibility-weighted MR imaging.
Kickingereder P; Wiestler B; Sahm F; Heiland S; Roethke M; Schlemmer HP; Wick W; Bendszus M; Radbruch A
Radiology; 2014 Sep; 272(3):843-50. PubMed ID: 24814181
[TBL] [Abstract][Full Text] [Related]
34. Combined analysis of MGMT methylation and dynamic-susceptibility-contrast MRI for the distinction between early and pseudo-progression in glioblastoma patients.
Bani-Sadr A; Berner LP; Barritault M; Chamard L; Bidet CM; Eker OF; Hermier M; Guyotat J; Jouanneau E; Meyronet D; Gouttard S; D'Hombres A; Iziquierdo C; Honnorat J; Berthezène Y; Ducray F
Rev Neurol (Paris); 2019 Oct; 175(9):534-543. PubMed ID: 31208813
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of perfusion MR imaging of high-grade astrocytomas: long-term follow-up study.
Hirai T; Murakami R; Nakamura H; Kitajima M; Fukuoka H; Sasao A; Akter M; Hayashida Y; Toya R; Oya N; Awai K; Iyama K; Kuratsu JI; Yamashita Y
AJNR Am J Neuroradiol; 2008 Sep; 29(8):1505-10. PubMed ID: 18556364
[TBL] [Abstract][Full Text] [Related]
36. Dynamic susceptibility contrast-enhanced perfusion magnetic resonance (MR) imaging combined with contrast-enhanced MR imaging in the follow-up of immunogene-treated glioblastoma multiforme.
Stenberg L; Englund E; Wirestam R; Siesjö P; Salford LG; Larsson EM
Acta Radiol; 2006 Oct; 47(8):852-61. PubMed ID: 17050367
[TBL] [Abstract][Full Text] [Related]
37. Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors.
Paulson ES; Schmainda KM
Radiology; 2008 Nov; 249(2):601-13. PubMed ID: 18780827
[TBL] [Abstract][Full Text] [Related]
38. Posttreatment recurrence of malignant brain neoplasm: accuracy of relative cerebral blood volume fraction in discriminating low from high malignant histologic volume fraction.
Gasparetto EL; Pawlak MA; Patel SH; Huse J; Woo JH; Krejza J; Rosenfeld MR; O'Rourke DM; Lustig R; Melhem ER; Wolf RL
Radiology; 2009 Mar; 250(3):887-96. PubMed ID: 19244052
[TBL] [Abstract][Full Text] [Related]
39. Interobserver variability in the radiological assessment of magnetic resonance imaging (MRI) including perfusion MRI in glioblastoma multiforme.
Kerkhof M; Hagenbeek RE; van der Kallen BF; Lycklama À Nijeholt GJ; Dirven L; Taphoorn MJ; Vos MJ
Eur J Neurol; 2016 Oct; 23(10):1528-33. PubMed ID: 27424939
[TBL] [Abstract][Full Text] [Related]
40. Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas.
Law M; Oh S; Johnson G; Babb JS; Zagzag D; Golfinos J; Kelly PJ
Neurosurgery; 2006 Jun; 58(6):1099-107; discussion 1099-107. PubMed ID: 16723889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
